Nationwide Recall Issued for “DTF Sexual Chocolate” Due to Undeclared Erectile Dysfunction Pharma Ingredients

Nalpac, a company that purchases and resells products, has initiated a voluntary nationwide recall of its “DTF Sexual Chocolate” due to the undeclared presence of sildenafil and tadalafil, according to a company announcement. These pharmaceutical ingredients are commonly found in prescription medications for erectile dysfunction.

The recalled product, DTF Sexual Chocolate, contains sildenafil and tadalafil, which are the active components in FDA-approved prescription drugs Viagra and Cialis, respectively. These medications are intended for use under the guidance of a licensed healthcare professional. The undeclared presence of these substances in the chocolate product poses a risk, particularly for individuals taking prescription medications containing nitrates. Such interactions could lead to a dangerous drop in blood pressure. Nalpac has stated that it has not received any reports of adverse events associated with this recall.

The product in question is packaged in cases containing 20 individual retail units. Consumers can identify the recalled item by its UPC code, 757817783069, which is printed on the product label. DTF Sexual Chocolate was available for purchase through adult retail stores, as well as online via the websites shopsexology.com and royalsins.com. The company is not the manufacturer of this product but is taking steps to recall it.

Nalpac is notifying its customers via email about the recall and is coordinating the return of all affected products. Consumers and retailers who possess the recalled DTF Sexual Chocolate are advised to cease selling or using the product immediately. They should either return the product to the place of purchase or discard it.

For any questions regarding this recall, consumers can contact Nalpac directly by phone at 248-541-1140 or by email at sales@nalpac.com. The company can be reached Monday through Friday, between 8:00 am and 4:30 pm Eastern Time. Individuals who have experienced any health issues they believe may be related to consuming this product are encouraged to consult with their physician or healthcare provider.

The U.S. Food and Drug Administration (FDA) is aware of this recall, which is being conducted with their knowledge. Consumers who experience adverse reactions or identify quality issues with this product are urged to report these incidents to the FDA’s MedWatch Adverse Event Reporting program. Reports can be submitted online via http://www.fda.gov/medwatch/report.htm, or by mail or fax using a form that can be downloaded from http://www.fda.gov/MedWatch/getforms.htm or requested by calling 1-800-332-1088.

Article by Mel Anara, based upon information from the U.S. Food and Drug Administration.

---